HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The Fragrance Counter

This article was originally published in The Rose Sheet

Executive Summary

Allou Health & Beauty sells controlling interest in its Internet beauty store The Fragrance Counter to The Subdury Group for $37.5 mil. About $17.5 mil. will be spent on building the Web site into an "Internet portal of beauty and well-being," Allou said. Using the expertise of its new investor, Allou will work to attract women of varied demographics to the site. The company has received about $19 mil. of the purchase price, which will result in a 28% increase in shareholder equity and negate anticipated losses, Allou said. The Subdury Group is led by venture capitalist Samuel Waksal, PhD, who has also served as CEO at ImClone Systems. Martha Stewart and Ogilvy & Mather CEO Charlotte Beers sit on Sudbury's board

You may also be interested in...



Ibeauty.com Holiday Orders Up 77% Week Before Christmas

Ibeauty.com generated a 41% increase in the number of online orders from Nov. 25 to Dec. 22 compared to the year-ago period, the company announced. In the week prior to Christmas, the beauty e-tailer reported a 77.8% increase in orders processed over the same period in 1998.

OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"

With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program

Latest Headlines
See All
UsernamePublicRestriction

Register

RS006598

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel